MK-7123-034: A Phase II Study of Navarixin (MK-7123) in Combination with Pembrolizumab (MK-3475) in Participants with Selected Advanced/Metastatic Solid Tumors

April 06, 2018
https://clinicaltrials.gov/ct2/show/NCT03473925
Solid Tumors
Principal Investigator: Ding Wang, MD
Advanced/Metastatic Solid Tumors
Accepting Participants
(313)916-1784